Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers (CONDUCT I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02166294
Recruitment Status : Terminated (Sponsor decision)
First Posted : June 18, 2014
Last Update Posted : June 27, 2017
Sponsor:
Information provided by (Responsible Party):
Amniox Medical, Inc.

Brief Summary:
In this randomized, multi-center, cross-over study, the efficacy and safety of NEOX® CORD 1K will be evaluated in patients suffering from non-healing diabetic foot ulcers. NEOX® CORD 1K is a cryopreserved human Amniotic Membrane and Umbilical Cord (AM/UC) matrix intended for use as a wound covering for dermal ulcers and defects. It is designated as a Human Cell & Tissue Product (HCT/P) by the U.S. FDA.

Condition or disease Intervention/treatment Phase
Foot Ulcer, Diabetic Other: NEOX® CORD 1K Procedure: Standard of Care (Pressure Bandage) Not Applicable

Detailed Description:
Patients identified for the study will have a non-healing diabetic ulcer, between 1-25cm² in size. The patient's wound(s) will be monitored for 2 weeks to document the wound pathology. Patients with less than 30% wound area reduction during the 2 week screening period and who meet all of the inclusion and none of the exclusion criteria, will be enrolled in the study. All patients will be assigned to a study or control group and undergo sharp debridement. NEOX® CORD 1K matrix will be applied to the treatment group on the day of debridement, covered with a wound veil, and standard dressing. Both groups will be monitored weekly, and the % decrease in wound size will be recorded at Baseline and Weeks 1, 2, 3, 4, 6, 8 and 12. If the wound is not progressing, additional application of NEOX® CORD 1K may be applied. The time to complete closure will be recorded for both groups. The study duration will be 12 weeks. Subjects in the control group that continue to suffer a non-healing wound at the week 12 visit will be offered an opportunity to cross-over to NEOX treatment and followed for an additional 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks
Study Start Date : June 2014
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NEOX® CORD 1K
Cryopreserved, umbilical cord allograft (NEOX® CORD 1K) with off-loading instructions.
Other: NEOX® CORD 1K
Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
Other Names:
  • cryopreserved, umbilical cord allograft
  • cryopreserved human amniotic membrane and umbilical cord
  • c-hAMUC
  • AM/UC

Active Comparator: Pressure bandage
Standard of Care Pressure bandage with off-loading instructions
Procedure: Standard of Care (Pressure Bandage)
Standard of Care wound, pressure dressing applied as needed at each visit.

Experimental: Standard of Care Cross over to NEOX
Subjects in the Standard of Care (pressure bandage) group that have not healed greater than 50% at the Week 12 visit, or have a wound that is worsening, will be offered participation in the cross-over arm of the trial. The cross-over arm of the study will be treated with NEOX CORD 1K and followed for 12 weeks.
Other: NEOX® CORD 1K
Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
Other Names:
  • cryopreserved, umbilical cord allograft
  • cryopreserved human amniotic membrane and umbilical cord
  • c-hAMUC
  • AM/UC

Procedure: Standard of Care (Pressure Bandage)
Standard of Care wound, pressure dressing applied as needed at each visit.




Primary Outcome Measures :
  1. Complete wound closure [ Time Frame: 12 weeks ]
    Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator

  2. Number of participants with adverse events [ Time Frame: 12 weeks ]
    Number of participants with adverse events will be compared between the two groups.


Secondary Outcome Measures :
  1. Number of applications [ Time Frame: 12 weeks ]
    Number of applications of study product (up to 12 weeks from Baseline)

  2. Blinded Reader Assessment [ Time Frame: 12 weeks and 24 weeks ]
    Percent of wounds achieving complete closure per the assessment of a Blinded Reader (by blinded photograph of wound and measurement acetate).

  3. Time to Initial Wound Closure [ Time Frame: Up to 12 weeks or 24 weeks (Crossover) ]
    Time to initial wound closure (Up to12 weeks from Baseline or 24 weeks for crossover group)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Between 18 years and 80 years of age inclusive
  2. Confirmed diagnosis of Type I or Type II Diabetes
  3. Males and Females diagnosed with a diabetic foot ulcer that is 1-25cm²
  4. At least one foot ulcer that is UT Grade IA
  5. Evidence of proper circulation which includes: An Index Ulcer defined as chronic (presence of wound for > 4 weeks) but not present for more than 52 weeks at the Screening Visit
  6. The Index Ulcer is located below the malleoli on the plantar or dorsal surface of the foot
  7. The Index Ulcer extends into the dermis or subcutaneous tissue with no evidence of exposed muscle, tendon, bone, or joint capsule
  8. Wound is free of necrotic debris and clinical signs of infection
  9. Patient has adequate circulation to the foot
  10. In patients with non-compressible ankle vessels there is adequate flow to the foot.

Exclusion Criteria:

  1. The Index Ulcer is of non-diabetic pathophysiology and/or over an active Charcot deformity
  2. The Index Ulcer is UT Grade IB or higher (worsening)
  3. Gangrene is present on any part of the affected foot
  4. The longest dimension of the Index Ulcer exceeds 5 cm at the Baseline Visit
  5. Patient is currently receiving renal dialysis
  6. Patient has a glycated hemoglobin A1c (HbA1c) level of > 12%
  7. Patient has significant renal impairment
  8. Chronic oral steroid use > 7.5 mg daily
  9. Requiring intravenous (IV) antibiotics to treat the index wound infection
  10. Patient has an ulcer within 15cm of the Index Ulcer identified for study consideration
  11. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents
  12. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)
  13. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including fever or purulent drainage from the wound site
  14. Patient has active malignancy other than non-melanoma skin cancer
  15. Patient's Index Ulcer has decreased by ≥ 30% during 2-week screening period
  16. Patient has untreated alcohol or substance abuse at the time of screening
  17. Pregnant women
  18. Patient is currently enrolled or participated in another investigational device, drug, or biologic trial within 60 days of screening
  19. Patient has allergy to primary or secondary dressing materials used in this trial
  20. Patient has an allergy to amphotericin-B or Dulbecco's Modified Eagle Medium (DMEM)
  21. Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with enzymes, growth factors, living skin, dermal substitutes or other advanced biological therapies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02166294


Locations
Layout table for location information
United States, Arizona
University of Arizona
Tucson, Arizona, United States, 85724
United States, California
Center for Clinical Research, Inc.
Castro Valley, California, United States, 94115
United States, Georgia
Ankle and Foot Centers of Georgia
Newnan, Georgia, United States, 30265
Sponsors and Collaborators
Amniox Medical, Inc.
Investigators
Layout table for investigator information
Study Director: Charles I. Romano Amniox Medical, Inc.

Layout table for additonal information
Responsible Party: Amniox Medical, Inc.
ClinicalTrials.gov Identifier: NCT02166294     History of Changes
Other Study ID Numbers: NE-2001
First Posted: June 18, 2014    Key Record Dates
Last Update Posted: June 27, 2017
Last Verified: June 2017
Keywords provided by Amniox Medical, Inc.:
Foot
Ulcer
Diabetes
Amputation
Limb salvage
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases